Summary of key recommendations: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 8: | Line 8: | ||
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | | colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.'''Clinical ASCVD | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.'''Clinical ASCVD (includes acute coronary syndromes, history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease presumed to be of atherosclerotic origin)''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki> | ||
*Age 75 y and no safety concerns: High-intensity statin | |||
*Age >75 y or safety concerns: Moderate-intensity statin | *Age >75 y or safety concerns: Moderate-intensity statin | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.'''Primary prevention – Primary LDL-C ‡190 mg/dL | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.'''Primary prevention – Primary LDL-C ‡190 mg/dL''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | ||
*Rule out secondary causes of hyperlipidemia | *Rule out secondary causes of hyperlipidemia | ||
*Age !21 y: High-intensity statin | *Age !21 y: High-intensity statin | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''3.'''Primary preventiondDiabetes 40–75 years of age and LDL-C 70–189 mg/dL | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''3.'''Primary preventiondDiabetes 40–75 years of age and LDL-C 70–189 mg/dL | ||
Revision as of 17:55, 27 October 2016
Template:Hypercholesterolemia Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Summary of Key Recommendations for the Treatment of Blood Cholesterol to Reduce ASCVD Risk in Adults
| Class I |
"1.Clinical ASCVD (includes acute coronary syndromes, history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease presumed to be of atherosclerotic origin)(Level of Evidence: A)"
|
"2.Primary prevention – Primary LDL-C ‡190 mg/dL(Level of Evidence: B)"
|
"3.Primary preventiondDiabetes 40–75 years of age and LDL-C 70–189 mg/dL
|
"4. Primary prevention – No diabetes 40–75 years of age and LDL-C 70–189 mg/dL
|
| Class III (Harm) |
| "1. RECOMMENDATION 1 HERE (Level of Evidence: C)" |
| "2. RECOMMENDATION 2 HERE (Level of Evidence: C)" |
| Class III (No Benefit) |
| "1. RECOMMENDATION 1 HERE (Level of Evidence: C)" |
| "2. RECOMMENDATION 2 HERE (Level of Evidence: C)" |
| Class IIa |
| "1. RECOMMENDATION 1 HERE (Level of Evidence: C)" |
| "2. RECOMMENDATION 2 HERE (Level of Evidence: C)" |
| Class IIb |
| "1. RECOMMENDATION 1 HERE (Level of Evidence: C)" |
| "2. RECOMMENDATION 2 HERE (Level of Evidence: C)" |